Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 97 articles:
HTML format



Single Articles


    March 2024
  1. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    PubMed     Abstract available


    February 2024
  2. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    PubMed     Abstract available


  3. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    PubMed     Abstract available


  4. WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al
    The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241.
    PubMed     Abstract available


  5. LOEB S, Hua Q, Bauer SR, Kenfield SA, et al
    Plant-based diet associated with better quality of life in prostate cancer survivors.
    Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172.
    PubMed     Abstract available


  6. HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al
    Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221.
    PubMed     Abstract available


  7. DORFF TB, Bryce AH
    Challenges in clinical trials for high-risk but curable prostate cancer.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245.
    PubMed    


  8. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    PubMed     Abstract available


    January 2024
  9. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    PubMed     Abstract available


  10. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    PubMed     Abstract available


  11. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    PubMed     Abstract available


    December 2023
  12. FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al
    Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168.
    PubMed     Abstract available



  13. FDA approves new combined treatment for advanced prostate cancer.
    Cancer. 2023;129:3841-3842.
    PubMed    


  14. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Reply to "Contextualizing racial associations in prostate cancer to expose structural causes".
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167.
    PubMed    


  15. ROLLIN FG, Olsen E, George M
    Contextualizing racial associations in prostate cancer to expose structural causes.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157.
    PubMed    


  16. GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al
    The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Cancer. 2023;129:3790-3796.
    PubMed     Abstract available


    November 2023
  17. YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al
    Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
    Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133.
    PubMed     Abstract available


  18. NIERENGARTEN MB
    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.
    PubMed    


  19. BRAWLEY OW, Ramalingam R
    The enigma of race and prostate cancer.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032.
    PubMed    


  20. LEE KM, Bryant AK, Lynch JA, Robison B, et al
    Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979.
    PubMed     Abstract available


    October 2023
  21. NIERENGARTEN MB
    Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities.
    Cancer. 2023;129:3192.
    PubMed    


  22. LEEMAN JE, Shin KY, Chen YH, Mak RH, et al
    Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Cancer. 2023;129:3044-3052.
    PubMed     Abstract available


    September 2023
  23. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Racial differences in serum chemokines in prostate cancer patients.
    Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012.
    PubMed     Abstract available


  24. JACKSON-SPENCE F, Young M, Sweeney C, Powles T, et al
    Top advances of the year: Genitourinary cancer.
    Cancer. 2023;129:2603-2609.
    PubMed     Abstract available


    August 2023
  25. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
    Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
    Cancer. 2023;129:2522-2531.
    PubMed     Abstract available


  26. NIERENGARTEN MB
    Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression.
    Cancer. 2023;129:2277.
    PubMed    


  27. NIERENGARTEN MB
    Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
    Cancer. 2023;129:2278.
    PubMed    


    July 2023
  28. JOHNSTONE PAS
    Magnetic resonance guidance is enough for prostate cancer: save adaptation for the patients it will really help.
    Cancer. 2023 Jul 24. doi: 10.1002/cncr.34835.
    PubMed    


  29. KICIAK A, Clark W, Uhlich M, Letendre A, et al
    Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.
    Cancer. 2023 Jul 10. doi: 10.1002/cncr.34812.
    PubMed     Abstract available


    June 2023
  30. HERR DJ, Elliott DA, Duchesne G, Stensland KD, et al
    Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.
    Cancer. 2023 Jun 30. doi: 10.1002/cncr.34916.
    PubMed     Abstract available


  31. HORNY M, Yabroff KR, Filson CP, Zheng Z, et al
    The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
    Cancer. 2023 Jun 17. doi: 10.1002/cncr.34905.
    PubMed     Abstract available


    May 2023
  32. MURPHY AB
    An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34886.
    PubMed     Abstract available


  33. RENCSOK EM, Stopsack KH, Slopen N, Odedina FT, et al
    Experience with the US health care system for Black and White patients with advanced prostate cancer.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34885.
    PubMed     Abstract available


  34. NIERENGARTEN MB
    MRI-guided radiotherapy results in fewer toxicities for localized prostate cancer.
    Cancer. 2023;129:1303-1304.
    PubMed    


    April 2023
  35. WEINER AB, Liu Y, Hakansson A, Zhao X, et al
    A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
    Cancer. 2023 Apr 14. doi: 10.1002/cncr.34790.
    PubMed     Abstract available


    March 2023
  36. MCDONALD AM, DeMora L, Yang ES, Hoyle JM, et al
    Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
    Cancer. 2023;129:685-696.
    PubMed     Abstract available


    February 2023
  37. NYAME YA, Holt SK, Etzioni RD, Gore JL, et al
    Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
    Cancer. 2023 Feb 13. doi: 10.1002/cncr.34681.
    PubMed     Abstract available


  38. CENAT JM, Dromer E, Darius WP, Dalexis RD, et al
    Incidence, factors, and disparities related to cancer among Black individuals in Canada: A scoping review.
    Cancer. 2023;129:335-355.
    PubMed     Abstract available


    January 2023

  39. Gut microbiota differs significantly between men with and without prostate cancer.
    Cancer. 2023;129:169-170.
    PubMed    


  40. FANG AM, Shumaker LA, Rais-Bahrami S
    Reply to "Micro-ultrasound may significantly reduce the proportion of unnecessary prostate biopsies in patients with PI-RADS 3 lesions".
    Cancer. 2023;129:322.
    PubMed    


  41. AVOLIO PP, Lazzeri M, Buffi NM, Lughezzani G, et al
    Micro-ultrasound may significantly reduce the proportion of unnecessary prostate biopsies in patients with PI-RADS 3 lesions.
    Cancer. 2023;129:320-321.
    PubMed    



  42. Metastasis-directed therapy plus hormone therapy improves progression-free survival for advanced prostate cancer.
    Cancer. 2023;129:9.
    PubMed    


    December 2022
  43. FECTEAU R, Lee WR
    The importance of body composition in patients with prostate cancer receiving radiotherapy.
    Cancer. 2022 Dec 29. doi: 10.1002/cncr.34594.
    PubMed    


    November 2022

  44. MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis.
    Cancer. 2022;128:3906.
    PubMed    


  45. RIVIERE P, Kalavacherla S, Banegas MP, Javier-Desloges J, et al
    Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34530.
    PubMed     Abstract available


  46. TAN WP, Kotamarti S, Chen E, Mahle R, et al
    Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Cancer. 2022;128:3824-3830.
    PubMed     Abstract available


    October 2022

  47. Men with prostate cancer at higher risk of venous thromboembolism.
    Cancer. 2022;128:3585.
    PubMed    


    September 2022
  48. KOWALCHUK RO, Kim H, Harmsen WS, Jeans EB, et al
    Cost effectiveness of treatment strategies for high risk prostate cancer.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34450.
    PubMed     Abstract available


  49. LILLARD JW JR, Moses KA, Mahal BA, George DJ, et al
    Racial disparities in Black men with prostate cancer: A literature review.
    Cancer. 2022 Sep 6. doi: 10.1002/cncr.34433.
    PubMed     Abstract available


    August 2022
  50. HILSCHER M, Roder A, Helgstrand JT, Klemann N, et al
    Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
    Cancer. 2022 Aug 17. doi: 10.1002/cncr.34407.
    PubMed     Abstract available


    July 2022
  51. FANG AM, Shumaker LA, Martin KD, Jackson JC, et al
    Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Cancer. 2022 Jul 12. doi: 10.1002/cncr.34355.
    PubMed     Abstract available


  52. O'ROURKE K
    Can multiparametric ultrasound be used for prostate cancer?
    Cancer. 2022;128:2399.
    PubMed    


    June 2022
  53. NNATE DA, Ball J
    Current prostate cancer screening and treatment strategies may not support a holistic nationwide program.
    Cancer. 2022 Jun 1. doi: 10.1002/cncr.34337.
    PubMed     Abstract available


    March 2022
  54. MENDES AA, Lu J, Kaur HB, Zheng SL, et al
    Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Cancer. 2022 Mar 25. doi: 10.1002/cncr.34190.
    PubMed     Abstract available


  55. O'ROURKE K
    Gut microbiome linked to aggressive prostate cancer.
    Cancer. 2022;128:938.
    PubMed    


    February 2022
  56. MCDONALD AC, Gernand J, Geyer NR, Wu H, et al
    Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
    Cancer. 2022 Feb 23. doi: 10.1002/cncr.34128.
    PubMed     Abstract available


    January 2022
  57. WITTMANN D, Mehta A, Bober SL, Zhu Z, et al
    TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results.
    Cancer. 2022 Jan 5. doi: 10.1002/cncr.34076.
    PubMed     Abstract available


    December 2021
  58. TILBURT JC, Zahrieh D, Pacyna JE, Petereit DG, et al
    Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
    Cancer. 2021 Dec 10. doi: 10.1002/cncr.34062.
    PubMed     Abstract available


  59. HAY A
    Stockholm3 tests improve prostate cancer screening.
    Cancer. 2021;127:4328-4329.
    PubMed    


    November 2021
  60. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    PubMed     Abstract available


  61. LIM JE, Huang J, Mnnist S, Weinstein SJ, et al
    Hair dye use and prostate cancer risk: A prospective analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.
    Cancer. 2021 Nov 19. doi: 10.1002/cncr.34035.
    PubMed     Abstract available


    September 2021
  62. KIRK PS, Zhu K, Zheng Y, Newcomb LF, et al
    Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
    Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911.
    PubMed     Abstract available


    August 2021
  63. PATEL HD, Koehne EL, Shea SM, Bhanji Y, et al
    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33875.
    PubMed     Abstract available


  64. EZENWANKWO EF, Nnaji CA
    Prostate cancer and the added burden of COVID-19 in sub-Saharan Africa: Rethinking regional priorities for responsive and data-driven cancer control programs.
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33887.
    PubMed    


  65. GARLAND SN, Savard J, Eisel SL, Wassersug RJ, et al
    A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33850.
    PubMed     Abstract available


  66. NIERENGARTEN MB
    Health literacy may determine treatment choice for favorable-risk prostate cancer: Results from a new trial show that men with low health literacy are less likely to choose active surveillance for prostate cancer after genomic testing.
    Cancer. 2021;127:2825-2826.
    PubMed    


  67. NECCHI A, Cucchiara V, Grivas P, Bratslavsky G, et al
    Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865.
    PubMed     Abstract available


  68. MEISSNER VH, Olze L, Schiele S, Ankerst DP, et al
    Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33836.
    PubMed     Abstract available


  69. BERGEROT CD, Williams SB, Klaassen Z
    Fear of cancer recurrence among patients with localized prostate cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33837.
    PubMed    


  70. COURTNEY PT, Deka R, Kotha NV, Cherry DR, et al
    Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33824.
    PubMed     Abstract available


    July 2021
  71. SERAPHIN TP, Joko-Fru WY, Hammerl L, Griesel M, et al
    Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33818.
    PubMed     Abstract available


  72. GREENBERG SA, Washington SL 3rd
    The state of our understanding of prostate cancer in sub-Saharan Africa.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33815.
    PubMed    


  73. FERRARO S, Rossi RS, Biganzoli EM
    Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33811.
    PubMed    


  74. KIM DW, Tilki D, D'Amico AV
    Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer and a Gleason score of 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33813.
    PubMed    


  75. PRINTZ C
    Prostate cancer in Black men responds better to immunotherapy.
    Cancer. 2021;127:2389.
    PubMed    


  76. KIM DW, Chen MH, Wu J, Huland H, et al
    Prostate-specific antigen levels of 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Cancer. 2021;127:2222-2228.
    PubMed     Abstract available


  77. PATEL DC, He H, Berry MF, Yang CJ, et al
    Cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible.
    Cancer. 2021;127:2302-2310.
    PubMed     Abstract available


    June 2021
  78. RUDE T, Walter D, Ciprut S, Kelly MD, et al
    Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration.
    Cancer. 2021 Jun 29. doi: 10.1002/cncr.33643.
    PubMed     Abstract available


  79. QUINN TP, Sanda MG, Howard DH, Patil D, et al
    Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33518.
    PubMed     Abstract available


  80. MCMAHON GC, Leapman MS
    A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk.
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33619.
    PubMed    


  81. HUDNALL MT, Desai AS, Tsai KP, Weiner AB, et al
    It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33621.
    PubMed     Abstract available


  82. HOWARD DH, Quek RGW, Fox KM, Arondekar B, et al
    The value of new drugs for advanced prostate cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33662.
    PubMed     Abstract available


  83. PARIKH RB, Gallo JJ, Wong YN, Robinson KW, et al
    Long-term depression incidence and associated mortality among African American and White prostate cancer survivors.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33656.
    PubMed     Abstract available


    May 2021
  84. HUNT TC, Ambrose JP, Haaland B, Kawamoto K, et al
    Decision fatigue in low-value prostate cancer screening.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33644.
    PubMed     Abstract available


  85. COLE AP, Herzog P, Iyer HS, Marchese M, et al
    Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
    Cancer. 2021 May 17. doi: 10.1002/cncr.33564.
    PubMed     Abstract available


  86. GEORGE DJ, Halabi S, Heath EI, Sartor AO, et al
    A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
    Cancer. 2021 May 5. doi: 10.1002/cncr.33589.
    PubMed     Abstract available


    April 2021
  87. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
    Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
    PubMed     Abstract available


  88. BAUER JE
    Prostate cancer survivorship, deaths, and health care management.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33588.
    PubMed    


  89. WEINER AB, Li EV, Desai AS, Press DJ, et al
    Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33584.
    PubMed     Abstract available


  90. ONDERDONK BE, Dorn PL, Martinez C, Arif F, et al
    A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33556.
    PubMed     Abstract available


  91. BITTERMAN DS, Chen MH, Wu J, Renshaw AA, et al
    Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33543.
    PubMed     Abstract available


  92. ALIBHAI SMH, Breunis H, Hansen AR, Gregg R, et al
    Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33523.
    PubMed     Abstract available


  93. IYER HS, Gomez SL, Chen JT, Trinh QD, et al
    Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33506.
    PubMed     Abstract available


    February 2021
  94. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    PubMed     Abstract available


    January 2021
  95. NGUYEN DD, Trinh QD, Cole AP, Kilbridge KL, et al
    Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
    Cancer. 2021;127:249-256.
    PubMed     Abstract available


  96. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
    Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
    Cancer. 2021;127:275-283.
    PubMed     Abstract available


    June 2020
  97. PRINTZ C
    Price transparency still an issue for cancer center costs.
    Cancer. 2020;126:2733.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.